Retinal ganglion cells die by apoptosis after optic nerve crush and in glaucoma, causing irreversible visual loss. Current therapies lower intraocular pressure, but are not designed specifically to prevent retinal ganglion cell death and blindness. Apoptosis can be initiated by at least two different pathways: activation of death receptors such as Fas, leading to recruitment of FADD, and caspase 8 to form the active caspase 8 containing death inducing signaling complex. This leads to cleavage and activation of downstream caspases and cell death. Alternatively, pro- apoptotic Bcl2 family members (dephosphorylated pBAD) can translocate to the mitochondrion, leading to release of cytochrome c, APAF-1, and activation of caspase-9, again initiating downstream caspases including caspase 3. We have observed that optic nerve crush induces rapid, stereotyped death of retinal ganglion cells, and that both of these pathways may well be involved. Although conceptualized as distinct pathways, they are likely points of intersection and regulation of these upstream initiating phenomenon. We propose that calcineurin activity is a major regulator of upstream caspases, because calcineurin inhibition protects against death receptor-initiated apoptosis and also prevents pBad phosphorylation. We demonstrated that treatment of rats with FK506, a widely clinically used immunosuppressant agent that is a potent calcineurin inhibitor, led to statistically significant retinal ganglion cell protection after optic nerve crush. The goals of the current application are (Aim 1) to determine whether inhibition of calcineurin underlies the observed neuroprotective effect of FK506, AND (Aim 2) to examine the effect of FK506 on the caspase 8/death receptor and pBad/cytochrome c initiating cascades.
Aim 3 builds on the first 2 aims, and takes advantage of a microsurgical vascular sclerosis model of experimental glaucoma in the rat. We observe that RGC are lost over the course of several weeks by apoptosis, with many of the same characteristics as we observe in the subacute optic nerve crush model. We will now further characterize this model, and determine whether calcineurin inhibition by FK506 is neuroprotective in this setting. Taken together, the broad, long-term aims of the studies outlined in this application are to characterize the cell death pathways involved in retinal ganglion cell death so that neuroprotective treatments can be developed for diseases in which retinal ganglion cells die, such as glaucoma.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
5R01EY013399-04
Application #
6876493
Study Section
Visual Sciences A Study Section (VISA)
Program Officer
Liberman, Ellen S
Project Start
2002-04-01
Project End
2006-12-31
Budget Start
2005-04-01
Budget End
2006-12-31
Support Year
4
Fiscal Year
2005
Total Cost
$259,000
Indirect Cost
Name
Massachusetts Eye and Ear Infirmary
Department
Type
DUNS #
073825945
City
Boston
State
MA
Country
United States
Zip Code
02114
Sun, Daniel; Qu, Juan; Jakobs, Tatjana C (2013) Reversible reactivity by optic nerve astrocytes. Glia 61:1218-35
Masland, Richard H (2012) The neuronal organization of the retina. Neuron 76:266-80
Wu, Hai-Yan; Hudry, Eloise; Hashimoto, Tadafumi et al. (2012) Distinct dendritic spine and nuclear phases of calcineurin activation after exposure to amyloid-? revealed by a novel fluorescence resonance energy transfer assay. J Neurosci 32:5298-309
Qu, Juan; Matsouaka, Roland; Betensky, Rebecca A et al. (2012) Calcineurin activation causes retinal ganglion cell degeneration. Mol Vis 18:2828-38
Hudry, Eloise; Wu, Hai-Yan; Arbel-Ornath, Michal et al. (2012) Inhibition of the NFAT pathway alleviates amyloid ? neurotoxicity in a mouse model of Alzheimer's disease. J Neurosci 32:3176-92
Qu, Juan; Wang, Danyi; Grosskreutz, Cynthia L (2010) Mechanisms of retinal ganglion cell injury and defense in glaucoma. Exp Eye Res 91:48-53
Wu, Hai-Yan; Hudry, Eloise; Hashimoto, Tadafumi et al. (2010) Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci 30:2636-49
Ergorul, Ceren; Ray, Arjun; Huang, Wei et al. (2010) Hypoxia inducible factor-1* (HIF-1*) and some HIF-1 target genes are elevated in experimental glaucoma. J Mol Neurosci 42:183-91
Huang, Wei; Fileta, John; Rawe, Ian et al. (2010) Calpain activation in experimental glaucoma. Invest Ophthalmol Vis Sci 51:3049-54
Fan, Bao Jian; Figuieredo Sena, Dayse R; Pasquale, Louis R et al. (2010) Lack of association of polymorphisms in elastin with pseudoexfoliation syndrome and glaucoma. J Glaucoma 19:432-6

Showing the most recent 10 out of 19 publications